Randomized phase II trial of CODE or amrubicin and cisplatin chemotherapy following concurrent cisplatin, etoposide and accelerated hyperfractionation thoracic radiotherapy for limited disease small cell lung cancer (JCOG1011, LD-SCLC/CODE vs AP)
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Amrubicin (Primary) ; Cisplatin; Doxorubicin; Etoposide; Vincristine
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 07 Nov 2017 Status changed from active, no longer recruiting to completed.
- 09 Sep 2015 Status changed from recruiting to active, no longer recruiting; according to an abstract presented at the 16th World Conference on Lung Cancer.
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer